AUTHOR CORRECTION

Love, D. C., Kochan, J., Cathey, R. L., Shin, S.-H. and Hanover, J. A. (2003). Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase. J. Cell Sci. 116, 647-654.

There were two errors in both the online and print versions of this paper. The second author J. Kochan was spelt incorrectly. In addition, a line was omitted from the acknowledgements. The correct author spelling and complete acknowledgement is shown below.

Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase
Dona C. Love1, Jarema P. Kochan2, R. Lamont Cathey1,*, Sang-Hoon Shin1 and John A. Hanover1,‡

1Laboratory of Cell Biochemistry and Biology, NIDDK, National Institutes of Health, Bethesda, MD, 20892, USA
2Department of Metabolic Diseases, Hoffman-La Roche Inc., 340 Kingsland Street, Nutley, NJ, 07110, USA
*Present address: Department of General Surgery, Carolinas Medical Center, Charlotte, NC 28232-2961, USA
‡Author for correspondence (e-mail: jah@helix.nih.gov)

The authors gratefully acknowledge William Prinz and Jenny Hinshaw for help and advice with mitochondrial subfractionation and electron microscopy, and the expert assistance of Charles Burghardt in the preparation of the OGT antibodies. The authors also thank William Lubas for helpful discussions and reagents.
Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase

Dona C. Love1, Jarema Kochran2, R. Lamont Cathey1,*, Sang-Hoon Shin1 and John A. Hanover1,‡

1Laboratory of Cell Biochemistry and Biology, NIDDK, National Institutes of Health, Bethesda, MD, 20892, USA
2Department of Metabolic Diseases, Hoffman-La Roche Inc., 340 Kingsland Street, Nutley, NJ, 07110, USA
*Present address: Department of General Surgery, Carolinas Medical Center, Charlotte, NC 28232-2861, USA
†Author for correspondence (e-mail: jah@helix.nih.gov)

Accepted 31 October 2002
Journal of Cell Science 116, 647-654 © 2003 The Company of Biologists Ltd
doi:10.1242/jcs.00246

Summary

O-linked GlcNAc transferase (OGT) mediates a novel glycan-dependent signaling pathway, but the intracellular targeting of OGT is poorly understood. We examined the localization of OGT by immunofluorescence microscopy, subcellular fractionation and immunoblotting using highly specific affinity-purified antisera. In addition to the expected nuclear localization, we found that OGT was highly concentrated in mitochondria. Since the mitochondrial OGT (103 kDa) was smaller than OGT found in other compartments (116 kDa) we reasoned that it was one of two predicted splice variants of OGT. The N-termini of these isoforms are unique; the shorter form contains a potential mitochondrial targeting sequence. We found that when epitope-tagged, the shorter form (mOGT; 103 kDa) concentrated in HeLa cell mitochondria, whereas the longer form (nOGT; 116 kDa) localized to the nucleus and cytoplasm. The N-terminus of mOGT was essential for proper targeting. Although mOGT appears to be an active transferase, O-linked GlcNAc-modified substrates do not accumulate in mitochondria. Using immunoelectron microscopy and mitochondrial fractionation, we found that mOGT was tightly associated with the mitochondrial inner membrane. The differential localization of mitochondrial and nucleocytoplasmic isoforms of OGT suggests that they perform unique intracellular functions.

Key words: OGT, O-GlcNAc, Glycan-dependent signaling, Mitochondria

Introduction

An increasing body of evidence suggests that the addition of O-linked GlcNAc by O-linked GlcNAc transferase (OGT) represents a signaling modification (Cole and Hart, 2001; Comer and Hart, 1999; Hanover, 2001; Roos and Hanover, 2000). This addition occurs at serine and threonine residues of cytosolic and nuclear proteins and, like phosphorylation, can change the function of such proteins as Sp1 and eNOS (Du et al., 2001; Yang et al., 2001). Other examples of substrates for the O-GlcNAcase are components of the nuclear pore complex (Nup 62, POM 121 and Nup180), transcription machinery (RNA polymerase II, SP1), transcription factors (c-myc, p53, and Rb) and structural proteins of the cytoplasm (cytokeratins, talin, and vinculin) (Hanover, 2001). Despite the vast array of proteins modified by OGT, these proteins share common characteristics: they are all part of macromolecular complexes and are phosphorylated and regulated throughout the cell cycle. Given the diverse substrates of OGT, understanding the structure and function of this enzyme is essential for understanding its regulation.

OGT is encoded by a single gene on the X chromosome (Akimoto et al., 1999; Kreppel et al., 1997; Lubas and Hanover, 2000; Lubas et al., 1997; Shafi et al., 2000). Gene knock-out experiments have shown that OGT is essential for stem cell viability (Hanover et al., 2002) and embryonic development (Shafi et al., 2000). OGT can be divided into three functional domains: an N-terminal tetratricopeptide region (TPR), a linker and a catalytic C-terminus. The reported OGT isoforms contain between 9-12 TPRs (Kreppel et al., 1997; Lubas and Hanover, 2000; Lubas et al., 1997). This conserved TPR domain is present in many proteins and is important for protein-protein interactions (Blatch and Lassle, 1999). Varying the number of TPR domains in OGT affects its substrate recognition (Lubas and Hanover, 2000). The linker region of OGT contains a nuclear localization sequence, consistent with a nuclear localization (Kreppel et al., 1997; Lubas et al., 1997). The proposed catalytic domain of OGT contains conserved amino acid domains that are present in other glycosyl transferases (Roos and Hanover, 2000; Wrabl and Grishin, 2001). Modest deletions in the C-terminus of OGT lead to dramatic reductions in enzymatic activity, supporting its role in catalysis (Lubas and Hanover, 2000).

The terminal product in the hexosamine biosynthetic pathway, UDP-GlcNAc, is utilized by OGT as a donor. A link between the hexosamine biosynthetic pathway and cellular glucose sensing by insulin has been established (Marshall et al., 1991; Traxinger and Marshall, 1991; Traxinger and Marshall, 1992). Further, overexpression of either the rate-limiting enzyme of the hexosamine biosynthetic pathway or OGT in the striated muscle and fat of transgenic mice leads to insulin resistance (Hebert et al., 1996; McClain et al., 2002; Tang et al., 2000; Veerababu et al., 2000). This insulin resistance was phenotypically similar to that observed in human type 2 diabetes. Additionally, recent studies have demonstrated a relationship between mitochondrial function, O-GlcNAc metabolism and maintenance of the diabetic state.
(Du et al., 2000; Nishikawa et al., 2000). Therefore it is likely that OGT, by utilizing the terminal product of hexosamine biosynthesis, may mediate many of the effects attributed to the dysregulation of this pathway.

Here we report the existence of two OGT isoforms differing in their subcellular localization. The shorter form associates with mitochondria in both primary and immortalized cells, whereas the longer form is nucleocytoplasmic. The N-terminus of the short form contains mitochondrial targeting information and is essential for mitochondrial localization. These data are discussed in terms of the role of differential targeting of OGT to the mitochondrial and nucleus in the regulation of a hexosamine-dependent signaling pathway.

**Materials and Methods**

**Plasmids**

pmOGT-myc was created by inserting a PCR product containing a BamHI site. Kozac consensus sequence and nucleotides spanning the atg start site to the XhoI site of mogt into pcDNA4/myc-His C (Invitrogen, Carlsbad, CA). pcnOGT-myc was created by digestion of pLKG1 (Kreppel et al., 1997), containing full-length rat cnOGT, with HindIII and XhoI. This purified fragment was inserted into pCDNA4myc His C (Invitrogen) using the same sites. Finally, pGFP-mOGT was created by digesting pLV4f (Lubas et al., 1997), encoding full-length mOGT, with EcoRV and BamHI and inserting the purified fragment into the EcoRI/C1 and BamHI sites of pEGFP-C2 (Invitrogen).

**Transfections**

HeLa cells were seeded on glass coverslips in six-well plates (Corning Incorporated, Corning, NY) at 1x10⁵ cells per well. Once cells were attached to the coverslips, they were transfected with indicated plasmids, using Fugene 6 (Roche, Indianapolis, IN) according to the manufacturer’s instructions.

**Antibodies**

Mouse anti-Cytochrome clone 26E3, used at 2 µg/ml, and clone 7H8.2C12, used at 0.5 µg/ml, were obtained from Zymed Laboratories (South San Francisco, CA). Anti-myc clone 9E10 (Roche) was used at 2 µg/ml. Anti-mitochondrial heat shock protein 70, clone JG1 (Affinity Bioreagents, Golden, CO) was used at a dilution of 1:500. Anti-O-linked N-Acetylglycosamine, clone RL2 (Affinity Bioreagents) was used at a dilution of 1:500. Anti-O-linked N-Acetylglycosamine, clone JG1 (Affinity Bioreagents) was used at 1:100, and CTD110.6 (Roche) was used at 2 µg/ml. Rabbit polyclonal antibody to OGT was generated and purified according to published methods (Baskin et al., 1999; Osborne et al., 1995).

**Immunolocalization**

HeLa cells CCL2 (ATCC, Manassas, VA) were grown as described (Love et al., 1998). Human aortic endothelial cells (Cascade Biologics, Portland, OR) were grown and maintained according to the supplier’s instructions. Cells were grown overnight on glass coverslips, then processed for immunolocalization. All cells were fixed with 4% formaldehyde (Ladd Research Industries, Williston, VT) in PBS (Mediatech, Herndon, VA) for 30 minutes at room temperature, washed three times in PBS, then permeabilized with 0.1% tritonX-100 (Calbiochem-Novabiochem Corporation, La Jolla, CA) for 3 minutes. After permeabilization, cells were washed three times in PBS and incubated with the primary antibodies for 1 hour at room temperature with gentle shaking. Primary antibodies were diluted in 5% goat serum, 2% BSA, in PBS. Following primary antibody incubation, cells were washed once for 15 minutes, then twice for 5 minutes before addition of appropriate, fluorescently conjugated, secondary antibodies (JacksonImmuno Research, West Grove, PA) for 1 hour at room temperature. Where indicated, MitoTracker® Red CM-H2Xros (Molecular Probes, Eugene, OR) was used to label respiring mitochondria according to manufacturer’s instructions. Cells were then washed three times in PBS and mounted on glass coverslips using Vectashield antifade mounting medium (Vector Laboratories, Inc., Burlingame, CA). All images were obtained using an Axioint 200M (Carl Zeiss Inc., Thornwood, NY) with an UltraView (Perkin Elmer, Wellesley, MA) spinning disk confocal scan head. Images were captured with a Quantix back-thinned EE57 CCD camera (Roper Scientific, Trenton, NJ) with binning set at two. All images were processed using OpenLab software (Improvision, Lexington, MA).

**Electron microscopy**

Purified mitochondria (4C Biotech, Seneffe, Belgium) were prepared and imaged by Paragon Biotech, Inc. (Baltimore, MD). Briefly, mitochondrial pellets were fixed with either 4% paraformaldehyde or 4% paraformaldehyde with 1% glutaraldehyde in 0.1 M phosphate buffer and processed for routine TEM embedding and sectioning and mounted onto nickel grids. The grids were incubated in 3% H2O2 in 0.1M PB for 5-15 minutes. After several rinses in PBS, grids were blocked with 0.5% BSA, 2% normal goat serum in PBS for 30 minutes. Sections were incubated with rabbit polyclonal OGT antiserum diluted 1:50 in PBS for 1 hour. Sections were then incubated with biotinylated, goat anti-rabbit secondary antibody at 1:400 (Vector) in PBS for 30 minutes at room temperature, followed by incubation with strepavidin gold conjugate (1:20, 10 nm gold particles) for 1 hour and rinsed in distilled water. The grids were double stained with uranyl acetate and lead citrate and observed and photographed using a Zeiss electron microscope.

**Biochemical isolation and separation of HeLa cells**

HeLa cell subcellular fractions were obtained from 4C Biotech. Mitochondria were separated into soluble proteins and membrane-associated proteins. Peripheral proteins were removed by incubating mitochondria in 1 M KCl for 30 minutes on ice, followed by centrifugation at 18,000 g for 30 minutes at 4°C. The mitochondrial pellet was resuspended at 30 mg/ml in 0.6 M sorbitol, 20 mM HEPES, pH 7.4, 2 mM MgCl2 supplemented with Complete Mini EDTA-free protease inhibitor cocktail tablets (Roche). The mitochondrial suspension was sonicated for three 10 second pulses using an Ultrasonic Processor XL (Misonix, Inc., Farmingdale, NY). Broken mitochondria were then centrifuged for 30 minutes at 100,000 g at 4°C to separate membrane-associated and soluble proteins. The membrane-associated proteins were then solubilized in 0.2% Triton X-100. The soluble proteins contained within the supernatant were precipitated by adding 0.0125% (w/v) sodium deoxycholate, then one fifth of the volume of 72% TCA for 30 minutes and centrifuged for 30 minutes at 18,000 g. Pellets were washed with ice cold acetone and recentrifuged. All pellets were resuspended in NuPAGE LDS sample buffer (Invitrogen). Mitoplasts were generated as described (Noma et al., 2001). Briefly, mitochondria were suspended in 20 mM HEPES-KOH, pH 7.4, and then placed in a test tube on ice for 30 minutes. The mitoplasts were recovered by centrifugation at 4000 g and then resuspended in 10 mM HEPES-KOH, pH 7.4, containing 220 mM mannitol and 70 mM sucrose. Alkaline extraction with carbonate buffer was performed as described previously (Lynn et al., 2001). Briefly, mitochondria and mitoplasts were resuspended in 100 mM sodium carbonate pH 11 for 30 minutes at 4°C, then centrifuged at 100,000 g.
OGT localizes to mitochondria

Western blot analysis

Protein samples were separated using NuPage® Bis-Tris gels (Invitrogen) and transferred to a nitrocellulose membrane for immunoblot analysis. Briefly, nitrocellulose membranes were blocked for 1 hour at room temperature with 5% nonfat dry milk with 0.1% Tween-20 (Sigma Chemical Corporation, St. Louis, MO), in Tris-buffered saline (Quality Biological, Incorporated, Gaithersburg, MD) (TBS-T). Primary antibodies were diluted in TBS-T containing 2% nonfat dry milk and incubated with the membrane. The horseradish-peroxidase-conjugated secondary antibodies (Jackson Immuno Research) were diluted in 2% BSA, 0.1% Tween 20, PBS. All antibody incubations were conducted for 1 hour at room temperature. Washes were conducted to remove the unbound primary and secondary antibodies and consisted of two quick washes in TBS-T or PBS-T, then one 15 minute and two 5 minute washes. Membranes were visualized using the Renaissance Chemiluminescence Reagent Plus Western Blot kit (NEN™ Life Science Products, Inc., Boston, MA) according to the manufacturer’s instructions.

Proteomics tools

The mitochondrial targeting sequence was predicted using iPSORT (http://www.hypothesiscreator.net/iPSORT/). The membrane-spanning region was predicted using TopPred 2 (http://bioweb.pasteur.fr/seqanal/interfaces/toppred.html).

Results

Intracellular localization of OGT isoforms

To better understand the function and regulation of OGT we examined the intracellular localization of the enzyme. We raised two highly specific rabbit polyclonal antisera and affinity purified them using recombinant human OGT. These antibodies recognize only known isoforms of OGT (see Fig. 1B, Fig. 4B,C). We then used these affinity-purified anti-OGT antibodies to detect OGT by immunofluorescence microscopy. OGT was localized to the nucleus as has been reported previously (Akimoto et al., 1999; Akimoto et al., 2000; Lubas et al., 1997) and also along cytoplasmic tubular structures suggestive of mitochondria. Dual staining of HeLa cells for OGT and for an abundant mitochondrial marker, cytochrome C oxidase, confirmed the mitochondrial localization of OGT (Fig. 1A). The merged image of OGT (green) and cytochrome C (red) revealed nearly perfect colocalization along mitochondria. In some areas, the OGT appears more punctate than did the cytochrome C (Fig. 1A). Colocalization of OGT in mitochondria was also demonstrated using mitochondrially targeted red fluorescent protein (data not shown). The mitochondrial localization of OGT was not cell type specific; a similar pattern was also detected in human aortic endothelial cells (HAEC), a primary cell line (Fig. 1A, bottom row) and in INS-1 cells (data not shown). Further verification of the mitochondrial localization of OGT was obtained using peptide antisera directed against amino acids 581-600 of OGT (data not shown). The immunofluorescent results were also verified by subcellular fractionation and immunoblotting. HeLa cells were fractionated by differential centrifugation and the subcellular fractions were examined by immunoblotting with anti-OGT. As shown in Fig. 1B, two species of OGT were detected by the antisera in total HeLa extracts. The relative levels of these two species (116 and 103 kDa) in the extract were somewhat variable and ranged from 5:1 to 1:1. When we examined the subcellular fractions, we found that the 103 kDa species was enriched in the mitochondrial fraction (mito) whereas the 116 kDa species was preferentially found in the nuclear fraction (nuclear). Densitometry of the bands in each of the fractions demonstrated that the ratio of 103 kDa to 116 kDa species was ~10-fold higher in the mitochondrial fraction, indicating significant enrichment of the 103 kDa species in the mitochondria. A similar enrichment of the mitochondrial marker, cytochrome c, was observed in this fraction (~12 fold; data not shown). Therefore, both our immunofluorescence and immunoblotting results suggested that
distinct forms of OGT reside in the nucleus and mitochondria; little OGT was found free in the cytoplasm.

Targeting information in OGT isoforms

In contrast to the expected nuclear localization of OGT, the striking mitochondrial localization we observed was surprising. The findings further suggested that the 103 kDa mitochondrial form of the enzyme might represent a distinct biochemical species (Fig. 1B). Several isoforms of OGT have been described which seem to arise by alternative splicing of the mammalian \textit{ogt} gene (Kreppel et al., 1997; Lubas et al., 1997; Nolte and Muller, 2002; Hanover et al., 2002). These known isoforms include species with predicted molecular weights of 116 (Kreppel et al., 1997) and 103 kDa (Lubas et al., 1997). We utilized several web-based search tools to identify regions of OGT that might target either of these isoforms to mitochondria. iPSORT identified a 20 amino-acid stretch at the unique N-terminal end of the 103 kDa isoform, which we designate mOGT (mitochondrial OGT) (Lubas et al., 1997), as the mitochondrial targeting sequence (Fig. 2A, bottom row). Interestingly, this mitochondrial targeting sequence was detected only when mOGT was designated as a plant protein, suggesting that this mitochondrial targeting sequence is somewhat unusual. The longer isoform of OGT, which we designate ncOGT (nucleocytoplasmic OGT) (Kreppel et al., 1997), did not contain a mitochondrial targeting sequence; instead, ncOGT contains a unique N-terminus and three additional TPRs when compared to mOGT (Fig. 2A, top row). Efforts to produce antipeptide antisera to distinguish between the two isoforms proved difficult. Therefore, to examine the targeting of these two OGT isoforms we expressed myc-tagged versions of mOGT and ncOGT (Fig. 2B). As we had previously documented that expressing the full-length, catalytically active mOGT was quite toxic (Lubas et al., 1997), we replaced the last 93 amino acids of the catalytic domains of ncOGT and mOGT with myc tags. We have previously shown that this deletion inactivates the catalytic activity of OGT (Lubas and Hanover, 2000). Immunolocalization of myc-tagged ncOGT indicated a somewhat diffuse pattern distributed throughout the nucleus and cytoplasm with no enrichment in mitochondria (Fig. 2Ba). By contrast, mOGT was associated with cytoplasmic structures highly suggestive of mitochondria (Fig. 2Bb). This localization was not epitope-tag-specific; the same localization pattern was observed when GFP was used instead of the myc epitope (data not shown). The importance of the N-terminus of mOGT for this unique targeting was demonstrated by deletion analysis. Removal of the first

**Fig. 2.** Identification of nucleocytoplasmic and mitochondrial isoforms of OGT. (A) A schematic of known OGT isoforms is shown to illustrate the unique N-termini. ncOGT (top row) contains 89 amino acids and an additional three TPRs, compared to mOGT (bottom row). mOGT contains a putative mitochondrial targeting sequence at its N-terminus (shown in red) and a predicted membrane-spanning helix (underlined). Both OGT isoforms are identical from the nine TPR region to their C-termini. (B) The 116 kDa (ncOGT) and 103 kDa (mOGT) isoforms of OGT were expressed in HeLa cells as a C-terminus myc-fusion. 24 hours following transfection cells were fixed and processed for indirect immunofluorescence using an anti-myc monoclonal antibody (a and b). ncOGT was distributed between the nucleus and cytoplasm and did not accumulate in mitochondria (Ba). By contrast, mOGT concentrated in cytoplasmic structures highly reminiscent of mitochondria (Bb; see below). The third panel (Bc) shows the cytoplasmic localization of GFP-ΔmOGT, which lacks the mitochondrial targeting region of mOGT. (C) The myc-tagged mOGT (Ca) colocalized with anti-OGT antibodies (Cb), which recognize both OGT isoforms. Colocalization was apparent only in the mitochondria; the tagged mOGT did not significantly colocalize with the endogenous nuclear OGT (Cc). The lower panels (Cd-f) show colocalization of mOGT (Cd) with MitoTracker® Red CM-H2XRos (Ce), a mitochondrial marker. The merged image shows colocalization in mitochondria (Cf). Bars, 10 μM.
15 amino acids of mOGT (GFP-ΔmOGT) prevented concentration in mitochondria and resulted in a primarily cytoplasmic localization, with a small amount found in the nucleus (Fig. 2Bc).

The N-terminus of mOGT is important for mitochondrial targeting
To confirm that the mOGT isoform is uniquely targeted to mitochondria, we colocalized myc-tagged mOGT with both endogenous OGT and with a mitochondrion-selective probe (Fig. 2C). As shown in the top panels, the myc-tagged mOGT colocalizes with the endogenous mitochondrial OGT, while showing little if any colocalization with the endogenous, nuclear OGT (Fig. 2Ca-c). The myc-tagged mOGT also colocalized with MitoTracker® Red CM-H2XRos, directly demonstrating mitochondrial targeting (Fig. 2Cd-f). Taken together, these data suggest that the unique N-terminus of mOGT contains targeting information essential for mitochondrial localization of mOGT.

O-GlcNAc-modified substrates do not accumulate in mitochondria
Although mOGT clearly localizes to mitochondria, biochemical and morphological findings suggest that only low levels of O-GlcNAc-modified substrates reside in mitochondria. As shown in Fig. 3A, when endogenous mitochondrial OGT (green) was colocalized with intracellular O-GlcNAc-modified proteins (red), no colocalization (yellow) was observed in the mitochondria. By contrast, nuclear OGT (Fig. 3A, green) and nuclear O-GlcNAc-modified proteins (Fig. 3A, red) show many areas of punctate localization. Another approach to visualizing the O-GlcNAc-modified proteins was taken by probing HeLa subcellular fractions with a monoclonal antibody (RL2) specific for O-GlcNAc-modified proteins (Fig. 3B). Multiple proteins ranging from 60 kDa to approximately 200 kDa were detected by RL2 and another monoclonal antibody CTD 110.6 (data not shown). These proteins were differentially enriched in the cytoplasm and nuclear fractions (Fig. 3B, cyto, nuc). The mitochondrial fraction, in comparison, was blank (Fig. 3B, mito). Only extreme overexposure of the western blot revealed very faint bands in the mitochondrial fraction (data not shown). Previous reports have shown that mitochondria contain the lowest amounts of cellular O-GlcNAc-modified proteins (Hanover et al., 1987; Holt and Hart, 1986). Taken together, these findings suggest that either mitochondrial OGT is catalytically inactive in this organelle or the substrates for OGT are very limited in mitochondria.

mOGT and catalytic activity
To demonstrate that the mOGT is capable of catalytic activity, we performed two kinds of experiments. First, we showed that mOGT is catalytically active when expressed in E. coli (Lubas and Hanover, 2000). Second, we replaced the mitochondrial targeting sequence of mOGT with GFP (GFP-ΔmOGT, see above) and expressed the protein in HeLa cells (Fig. 3C). GFP-ΔmOGT is not targeted to mitochondria but resides mainly in the cytoplasm, with trace amounts detected in the nucleus (Fig. 3C, GFP-ΔmOGT). Staining these transfected cells with RL2 showed enhanced glycosylation in the cytoplasm of cells overexpressing GFP-ΔmOGT (Fig. 3C, RL2). Taken together, these studies argue that mitochondrial OGT, although potentially active, is sequestered from the more abundant substrates found in the nucleus and cytoplasm.

Association of mOGT with the mitochondrial membrane
To determine the mitochondrial localization of OGT at higher resolution, purified HeLa cell mitochondria were examined by indirect immunogold electron microscopy using affinity-purified anti-OGT (Fig. 4A). We determined that approximately 75% of the total gold particles were associated with the mitochondrial membrane. Upon examining a large number of labeled mitochondria, the majority of the gold label was associated with the mitochondrial inner membrane (Fig. 4A). By contrast, when a control incubation was performed (Fig. 4A,
OGT is associated with the mitochondrial inner membrane.

(A) Immunogold staining of purified mitochondria demonstrates an inner membrane localization for OGT; no specific label was detected when the gold-labeled secondary antibody was used alone (negative control). Bars, 0.1 μM. (B) Purified HeLa mitochondria (whole) were fractionated by sonication and high-speed centrifugation into membrane and soluble protein fractions, separated on a 4-20% PAGE-gel, transferred to nitrocellulose and probed with OGT-specific, affinity-purified antibodies. Equal amounts of protein were loaded in each lane. The majority of mOGT was found associated with the membrane fraction after salt washing (see Materials and Methods). Fractionation of mitochondria was monitored by mtHSP 70 content. The bulk of this matrix marker appeared in the soluble fraction under conditions where mOGT remained membrane associated. (C) Localization of mOGT was compared in mitochondria and mitoplasts subjected to alkaline extraction with carbonate buffer. The outer membrane of mitochondria was removed by hypotonic lysis to produce the mitoplasts. Both mitochondria and the mitoplasts were washed with 100 mM sodium carbonate pH 11 to remove peripherally associated proteins. The soluble and membrane fractions were separated and probed for OGT. The arrows indicate that the mOGT is greatly enriched in the membrane fractions of both mitochondria and mitoplasts.

Discussion

We demonstrate the differential localization of two OGT isoforms, ncOGT and mOGT. The longer 116 kDa isoform (ncOGT) resides mainly in the nucleus, whereas the shorter 110 kDa (mOGT) isoform targets to mitochondria. The divergent N-terminus of mOGT contains mitochondrial targeting information that is essential for appropriate localization of mOGT. Immunolocalization and biochemical evidence suggests that mOGT associates with the mitochondrial inner membrane. The subcellular targeting of OGT implies that these isoforms perform different functions and allows for the integration of glucose sensing into different cellular pathways.

The regulation of the differing OGT isoforms

Our recent analysis of the mouse, rat (Hanover et al., 2002) and the human (Nolte and Muller, 2002) ogt gene suggests that the isoforms we have designated mOGT and ncOGT arise by alternative splicing from a single gene on the X-chromosome. The mOGT form utilizes intron 4 of ncOGT as an exon to generate its unique 5’ N-terminus. Interestingly, this intronic region of the ogt gene may also serve as an internal promoter driving the expression of only the mOGT isoform. Thus, the current evidence suggests that the two isoforms of OGT may be independently regulated. The mOGT and ncOGT isoforms
differ in a number of key respects. First, they differ in localization as we have demonstrated in this study. Second, they differ in the number of TPR motifs present; mOGT has nine repeats whereas the ncOGT has 12. Third, the unique N-termini of the two proteins may contain additional regulatory information unrelated to targeting. Given these differences, it is likely that the two OGT isoforms have very different substrates and intracellular functions.

Functional significance of OGT isoforms

O-GlcNAc addition and removal is dynamic and exhibits a complex interrelationship with protein phosphorylation. The O-GlcNAc modification has been implicated in a large number of diverse intracellular processes ranging from translational control, transcription, transcriptional repression, insulin resistance and regulation of the cell cycle (Hanover, 2001; Wells et al., 2001). These functions may have as a common theme the requirement for nutrient sensing and signaling through the hexosamine biosynthetic pathway (the hexosamine signaling pathway) (Hanover, 2001; Wells et al., 2001). Although the TPR domain of OGT is capable of interacting with many proteins, it is difficult to understand how one enzyme derived from a single gene could mediate such diverse intracellular functions. The model shown in Fig. 5 summarizes how the differentially targeted isoforms may contribute to hexosamine-dependent intracellular signaling. Transcripts derived from a single mammalian OGT gene on chromosome X are alternatively spliced to produce mOGT and ncOGT. The mOGT and ncOGT isoforms are likely to perform unique functions in the mitochondrion and nucleus in response to changing levels of a common precursor: UDP-GlcNAc. The mitochondrial mOGT may participate in such functions as apoptosis and the regulation of precursor transport and carbohydrate metabolism. The hexosamine pathway has been previously implicated in the regulation of apoptosis (Boehmelt et al., 2000; Hanover et al., 1999; Liu et al., 2000). In addition, we have shown that when overexpressed, the mOGT is highly toxic to cells (Lubas et al., 1999; Liu et al., 2000). The mitochondrial mOGT may play a role in apoptosis and lipid and carbohydrate metabolism or proapoptotic signals.

The unique N-terminus, additional TPRs and nucleocytoplasmic localization of ncOGT suggests that this isoform participates in the cytoplasmic and nuclear events attributed to O-GlcNAc such as translation, nuclear transport, transcriptional repression and chromatin remodeling (Datta et al., 1989; Hanover, 2001; Kelly and Hart, 1989; Wells et al., 2001). Most recently, ncOGT was shown to interact with the histone deacetylase complex by binding to the co-repressor mSin3a (Yang et al., 2002). By appropriate targeting of ncOGT by mSin3a, transcription can be negatively regulated through glycosylation and deacetylation. Therefore, the identification and characterization of the differentially targeted isoforms of OGT presented here should facilitate further dissection of the regulation of their unique intracellular functions.

The authors gratefully acknowledge William Prinz and Jenny Hinshaw for help and advice with mitochondrial subfractionation and electron microscopy. The authors also thank William Lubas for helpful discussions and reagents.

References

Akimoto, Y., Kreppel, L. K., Hirano, H. and Hart, G. W. (1999). Localization of the O-linked N-acetylgalactosamine transferase in rat pancreas. Diabetes 48, 2407-2413.

Akimoto, Y., Kreppel, L. K., Hirano, H. and Hart, G. W. (2000). Increased O-GlcNAc transferase in pancreas of rats with streptozotocin-induced diabetes. Diabetologia 43, 1239-1247.

Baskin, D. G., Schwartz, M. W., Seeley, R. J., Woods, S. C., Porte, D. J., Breininger, J. F., Jonak, Z., Schaefer, J., Krouse, M., Burghardt, C. et al. (1999). Leptin receptor long-form splice-variant protein expression in neuron cell bodies of the brain and co-localization with neuropeptide Y mRNA in the arcuate nucleus. J. Histochem. Cytochem. 47, 353-362.

Blutch, G. L. and Lassle, M. (1999). The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. Bioessays 21, 932-939.

Boehmelt, G., Wakeham, A., Elia, A., Sasaki, T., Plette, S., Potter, J., Yang, Y., Tsang, E., Ruland, J., Iscove, N. N. et al. (2000). Decreased UDP-GlcNAc levels abrogate proliferation control in E10.5 deficient cells. EMBO J. 19, 5092-5104.

Cole, R. N. and Hart, G. W. (2001). Cytosolic O-glycosylation is abundant in nerve terminals. J. Neurochem. 79, 1080-1089.

Conner, F. I. and Hart, G. W. (1999). O-GlcNAc and the control of gene expression. Biochim. Biophys. Acta. 1473, 161-171.

Datta, B., Ray, M. K., Chakrabartti, D., Wylie, D. E. and Gupta, N. K. (1989). Glycosylation of eukaryotic peptide chain initiation factor 2 (eIF-2)-associated 67-kDa polypeptide (p67) and its possible role in the inhibition
